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Abstract
Background: Studies in mice have shown that PPARa is an important regulator of hepatic lipid metabolism and the acute
phase response. However, little information is available on the role of PPARa in human liver. Here we set out to compare the
function of PPARa in mouse and human hepatocytes via analysis of target gene regulation.
Methodology/Principal Findings: Primary hepatocytes from 6 human and 6 mouse donors were treated with PPARa
agonist Wy14643 and gene expression profiling was performed using Affymetrix GeneChips followed by a systems biology
analysis. Baseline PPARa expression was similar in human and mouse hepatocytes. Depending on species and time of
exposure, Wy14643 significantly induced the expression of 362–672 genes. Surprisingly minor overlap was observed
between the Wy14643-regulated genes from mouse and human, although more substantial overlap was observed at the
pathway level. Xenobiotics metabolism and apolipoprotein synthesis were specifically regulated by PPARa in human
hepatocytes, whereas glycolysis-gluconeogenesis was regulated specifically in mouse hepatocytes. Most of the genes
commonly regulated in mouse and human were involved in lipid metabolism and many represented known PPARa targets,
including CPT1A, HMGCS2, FABP1, ACSL1, and ADFP. Several genes were identified that were specifically induced by PPARa
in human (MBL2, ALAS1, CYP1A1, TSKU) or mouse (Fbp2, lgals4, Cd36, Ucp2, Pxmp4). Furthermore, several putative novel
PPARa targets were identified that were commonly regulated in both species, including CREB3L3, KLF10, KLF11 and
MAP3K8.
Conclusions/Significance: Our results suggest that PPARa activation has a major impact on gene regulation in human
hepatocytes. Importantly, the role of PPARa as master regulator of hepatic lipid metabolism is generally well-conserved
between mouse and human. Overall, however, PPARa regulates a mostly divergent set of genes in mouse and human
hepatocytes.
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Introduction
The liver plays a major role in the coordination of lipid
metabolism. It actively metabolizes fatty acids as fuel and is
responsible for triglyceride export via synthesis of very low density
lipoproteins. An imbalance between these pathways may lead to
triglyceride accumulation and thus hepatic steatosis. Studies in
mice have indicated that many aspects of hepatic lipid metabolism
are under transcriptional control of the Peroxisome Proliferator
Activated Receptor a (PPARa), a transcription factor belonging to
the nuclear receptor superfamily. It is well established that
impaired PPARa function is associated with hepatic lipid
accumulation [1–3]. Consequently, synthetic agonists for PPARa
are explored for the treatment of non-alcoholic fatty liver disease
[4].
Besides PPARa, two other PPARs isotypes are known to exist:
PPARb/d and PPARc. The PPARs share a common mode of
action that involves heterodimerization with the nuclear receptor
RXR, followed by binding to PPAR response elements (PPREs) in
target genes [5]. Activation of transcription is induced by binding
of ligand, leading to recruitment of specific coactivator proteins
and dissociation of corepressors. Expression of PPARa and
PPARb/d is relatively ubiquitous, whereas PPARc is mainly
expressed in adipose tissue, macrophages and colon [6,7].
PPARa can be ligand-activated by endogenous agonists, which
include fatty acids and fatty acid derivatives such as eicosanoids
and oxidized fatty acids, as well as by various synthetic compounds
[5,8,9]. The latter group induces proliferation of peroxisomes in
rodents and are thus referred to as peroxisome proliferators.
Peroxisome proliferators encompass a diverse group of chemicals
ranging from herbicides and insecticides to industrial plasticisers,
halogenated hydrocarbons, and fibrate drugs [10,11].
Most of the research concerning PPARa has focused on its role
in the liver. A wealth of studies performed almost exclusively in
mice has revealed that PPARa serves as a key regulator of hepatic
fatty acid catabolism (reviewed in [12]). Using PPARa null mice, it
has been shown that PPARa is especially important for the
adaptive response to fasting by stimulating hepatic fatty acid
PLoS ONE | www.plosone.org 1 August 2009 | Volume 4 | Issue 8 | e6796
oxidation and ketogenesis [2,13,14]. In addition, PPARa has been
shown to govern liver inflammation, lipoprotein metabolism,
glucose metabolism, and hepatocyte proliferation [12,15,16]. The
latter response is known to be specific for rodents [17]. The
species-specific effects of PPARa agonists on hepatocyte prolifer-
ation and associated hepatocarcinogenesis were ascribed to a
number of factors including properties intrinsic to the PPARa
protein, conservation and functionality of PPREs in the promoter
of target genes, and presence or absence of co-regulators
depending on the cellular environment [18].
However, apart from the differential effect on hepatocyte and
peroxisome proliferation, it is not very clear whether PPARa has a
similar role in mice and humans and to what extent target genes
are shared between the two species. Based on the lower expression
level of PPARa in human liver compared to mouse liver [19], the
functionality of PPARa in human liver has been questioned [20].
This notion has been further reinforced by the limited impact of
PPARa agonists on lipid metabolism genes in HepG2 cells [21],
which represent the most widely used liver cell culture model.
However, a careful and comprehensive comparative analysis of
gene regulation by PPARa between mouse and human hepato-
cytes has yet to be performed. To fill this gap we systematically
compared the effect of activation of the transcription factor
PPARa in primary mouse and human hepatocytes using a whole
genome transcriptomics approach.
Results
PPARa plays an important role in primary human
hepatocytes
We first determined PPARa expression in mouse and human
liver by quantitative real-time PCR. PPARa mRNA was only
slightly lower in human liver compared to mouse liver (Figure 1A).
In order to study the effect of PPARa activation on gene
expression in human and mouse liver, primary human and mouse
hepatocytes were incubated with the PPARa agonist Wy14643 for
6 or 24 h. To minimize potential statistical bias, the diversity of the
six human donors was mimicked by performing the equivalent
mouse experiment in primary hepatocytes from six different mice
varying in age, sex and genetic background. The choice of using
Wy14643 as PPARa agonist was based on a pilot experiment in
which primary human hepatocytes were treated with equal
concentrations of either Wy14643 or fenofibrate (50 mM). In
general, we found that established PPARa target genes were more
strongly induced by Wy14643 compared to fenofibrate (data not
shown).
The expression of PPARa itself was similar between mouse and
human hepatocytes (Figure 1B). While in mouse hepatocytes
PPARa mRNA decreased during the course of the incubation, the
opposite was the case in human hepatocytes. Treatment with
Wy14643 consistently increased the expression of the established
PPARa targets Cpt1a and Pdk4 in mouse and human hepatocytes,
indicating activation of PPARa (Figure 1C).
To study the effect of PPARa activation on global gene
expression, microarray analysis was performed using Affymetrix
GeneChips.We first performed principal component analysis (PCA)
to sort out the major sources of variation in our microarray data.
The PCA plot for 6 h Wy14643 treatment clearly shows that the
principal source of variation is between the species (Figure S1).
Additionally, the results indicate that: 1) there is large variation
between the various mice at basal level (untreated cells), whereas the
variation between the human donors is small; 2) the effect of PPARa
activation is more pronounced in mice than in humans; 3) the effect
of PPARa activation is consistent between the various mice.
We found that in human hepatocytes Wy14643 treatment for
6 h significantly altered the expression of 705 genes. A
considerably larger number of genes were regulated by
Wy14643 in mouse hepatocytes (Figure 2). More stringent
selection dramatically reduced the number of significantly
regulated genes in human hepatocytes, while it had much less of
an effect in mouse hepatocytes (data not shown). Surprisingly,
more prolonged Wy14643 treatment augmented the number of
significantly regulated genes in human hepatocytes, but not in
mouse hepatocytes. The latter result may be related to the lower
expression of PPARa in mouse hepatocytes after prolonged
incubation (Figure 1B). Overall, these data demonstrate a major
impact of PPARa activation in human hepatocytes. All microarray
results have been deposited in to the Gene Expression Omnibus
(http://www.ncbi.nlm.nih.gov/projects/geo/) and can be ac-
cessed online under series number GSE17254.
PPARa regulates a mostly divergent set of genes in
mouse and human primary hepatocytes
We next determined the overlap in genes regulated by
Wy14643 in mouse and human hepatocytes. Data from 6 h and
24 h Wy14643 treatment were combined to prevent creating a
bias from possible differences in kinetics of gene regulation
between mouse and human and separate analyses were carried out
for up- and down-regulated genes. A total of 125 genes were found
to be induced by Wy14643 in both species, many of which were
involved in various aspects of lipid metabolism (Figure 3A). A
smaller number of genes was found to be downregulated by
Wy14643 in both species (Figure 3B). However, the far majority of
genes were regulated specifically in one of the species, which
would suggest that in general PPARa -dependent gene regulation
is poorly conserved between mouse and human. A complete list of
regulated genes in the various categories is available in Table S1.
To explore the possible functional impact of PPARa activation
in mouse and human hepatocytes, we analyzed for overrepresent-
ed Gene Ontology classes in response to Wy14643 treatment using
ErmineJ. Again, data from 6 h and 24 h Wy14643 treatment were
combined. Out of 115 GO classes overrepresented after Wy14643-
treatment of mouse hepatocytes, 48 showed overlap with human
hepatocytes (Figure 3C). The overlapping GO classes generally
represented various aspects of hepatic fatty acid metabolism
including peroxisomal metabolism (Table S2). The GO classes
specific for the mouse hepatocytes also mostly corresponded to
lipid metabolic pathways, suggesting that regulation of lipid
metabolism is the dominant function of PPARa in mouse
hepatocytes. In contrast, the GO classes specific for human
hepatocytes included alternative metabolic processes including bile
acid metabolic process, and various aspects of amino acid
metabolism.
A similar type of analysis focusing on upregulated genes was
carried out using gene set enrichment analysis (GSEA). Results
from Ingenuity were generally concordant with GSEA and will not
further be elaborated on here. Out of 33 pathways induced by
PPARa activation in mouse hepatocytes, 20 were also induced in
human hepatocytes (Figure 3D), Similar to GO analysis, pathways
commonly regulated in mouse and human were mostly related to
lipid metabolism (Table S3). Interestingly, the glycolysis-gluco-
neogenesis pathway was specifically upregulated by Wy14643 in
mouse (Figure 4A), while xenobiotic metabolism was specifically
upregulated in human (Figure 4B). Overall, these data show that
PPARa governs a mostly divergent set of genes in mouse and
human hepatocytes, although more significant overlap was
observed at the pathway level.
PPARa between Mouse and Human
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Identification of human and mouse-specific novel
putative PPARa target genes
In order to identify additional genes that are specifically
regulated by PPARa in one particular species, we performed
scatter plot analysis comparing the effect of 6 h PPARa activation
between mouse and human (Figure 5A). A similar plot was created
for 24 h PPARa activation (Figure 5B). A number of genes could
be identified that were induced by Wy14643 specifically in human
(MBL2, CYP1A1, HMOX1 and TSKU) or mouse (Fbp2, Lgals4,
Pxmp4 and Ucp2) . To directly compare the effect of Wy14643 on
specific genes between mouse and human, genes that were
upregulated by 6 h or 24 h Wy14643 in human hepatocytes were
Figure 1. Activation of PPARa in mouse and human hepatocytes. (A) PPARa mRNA expression levels in human versus mouse liver as
expressed relative to universal 18S. (B) PPARa mRNA expression levels in human versus mouse primary hepatocytes as expressed relative to universal
18S. Expression was determined at 6 h (open bars) and 24 h (black bars) in control-treated cells (DMSO). (C) Relative induction of expression of
carnitine palmitoyltransferase 1A (Cpt1a) and pyruvate dehydrogenase kinase 4 (Pdk4) was determined in human and mouse primary hepatocytes
treated with Wy14643 for 6 h (gray bars) and 24 h (black bars). Expression of cells treated with DMSO was set at 1 (white bars). Error bars represent
SD. *P,0.05 according to Student’s T-test.
doi:10.1371/journal.pone.0006796.g001
PPARa between Mouse and Human
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ranked according to their mean fold-change and the changes in
expression compared between the individual donors (Figure 6 and
Figure S2, respectively). The changes in expression of their mouse
orthologs are presented in parallel. The picture clearly illustrates
the human-specific induction of MBL2, ALAS1, TSKU, and
many other genes. The specific induction of TSKU was confirmed
by qPCR (Figure S3A). Interestingly, the top 50 of most highly
induced genes contain a remarkably high number of established
PPARa targets, regulation of which was conserved in mouse
hepatocytes. This includes genes involved in mitochondrial fatty
acid oxidation and ketogenesis (HMGCS2, CPT1A, CPT2,
SLC25A20), peroxisomal/microsomal fatty acid oxidation
(ECH1, CYP4A11), fatty acid binding and activation (FABP1,
ACSL1, ACSL3), and lipid droplet associated proteins (ADFP).
Wy14643 also stimulated expression of a number of secreted
PPARa targets including FGF21 and ANGPTL4. These data
support an important role for PPARa in the regulation of lipid
metabolism in human hepatocytes. Besides numerous known
PPARa target genes, several putative novel PPARa targets were
found to be commonly regulated by Wy14643 in mouse and
human, including the transcription factors CREB3L3, KLF10 and
KLF11, and MAP3K8. Induction of KLF10 was confirmed by
qPCR (Figure S3B).
Conversely, the scatter plots and ranking of genes also clearly
revealed numerous genes that were specifically induced by
Wy14643 in mouse, including Fbp2, Lgals4, and Pxmp4, as well
as known PPARa target genes such as Cd36, Cpt1b and Ucp2
(Figures 5B and 7 ; Figure S4). The mouse specific induction of
Fbp2 was confirmed by qPCR (Figure S3C). These data suggest
that in general the effect of PPARa activation is remarkably
dissimilar between mouse and human hepatocytes. Nevertheless,
many established PPARa targets representing key genes in lipid
metabolism are commonly regulated in mouse and human.
The role of PPARa in hepatic lipid metabolism is well
conserved between mouse and human
We showed that a large proportion of the genes commonly
regulated by PPARa in mouse and human were involved in some
aspect of lipid metabolism. To better appreciate the conservation
of PPARa’s role as master regulator of hepatic lipid metabolism,
we classified genes according to specific lipid metabolic pathways
to create a comprehensive picture of PPARa-dependent gene
regulation (Figures 8A and B). The picture reveals that in human
hepatocytes PPARa activation induces the expression of many
genes involved in different aspects of lipid metabolism, including
fat oxidation, fat synthesis, intracellular TG storage and hydrolysis,
membrane transport, intracellular activation and trafficking of
fatty acids and lipoprotein metabolism. Comparison with the
corresponding picture for mouse reveals a remarkable conserva-
tion at the pathway level, indicating that the role of PPARa in
hepatic lipid metabolism is highly similar between mice and
human. The sole exception is lipoprotein metabolism, represented
by APOA2 and APOA5, which was exclusively regulated in
human hepatocytes. It is also evident that fewer peroxisomal genes
are induced by Wy14643 in human vs. mouse hepatocytes.
Interestingly, within a particular metabolic pathway the specific
genes upregulated by Wy14643 to some extent differ between
mouse and human. Taken together, the results suggest that in
human and mouse hepatocytes PPARa has an equally important
role in governing lipid metabolism with the exception of
lipoprotein metabolism and to a lesser extent peroxisomal
metabolism. However, the specific genes under control of PPARa
in mouse and human are partially different.
Figure 2. Wy14643 treatment causes major changes in gene
expression in human and mouse hepatocytes. Bars show number
of up- and down-regulated genes in primary human and mouse
hepatocytes treated with Wy14643 for 6 h or 24 h. Genes were
considered significantly regulated if mean fold change (MFC).1.1 and
P,0.05.
doi:10.1371/journal.pone.0006796.g002
Figure 3. Limited overlap at individual gene level but major
overlap at pathway level. Venn diagrams showing overlap in
significantly upregulated (A) and (B) downregulated genes after
treatment with Wy14643 in mouse versus human hepatocytes. Genes
were included if they were significantly regulated by Wy14643 at 6 h
and/or 24 h. Criteria for significance was mean fold-change (MFC).1.1
and P,0.05. Genes without orthologs in the other species and/or not
present on the array of the other species were excluded. (C) Venn
diagram showing overlap in overrepresented Gene Ontology classes
upon Wy14643 treatment in mouse and human hepatocytes based on a
functional class score method. Data from 6 h and 24 h Wy14643
treatment were combined in a single analysis. Only GO classes
containing 8 to 125 genes and FDR,0.0001 were included in the Venn
diagram. (D) Venn diagram showing overlap in upregulated processes
analyzed by GSEA. Only gene sets having a size between 15 and 250
genes were included in the analysis. To account for multiple hypothesis
tasting, gene sets having a FDR,0.25 were selected. Sources of the
gene sets: BIOCARTA, GENMAPP, KEGG, SIGNALING ALLIANCE, SIGNAL-
ING TRANSDUCTION, GEARRAY and SK manual.
doi:10.1371/journal.pone.0006796.g003
PPARa between Mouse and Human
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Discussion
Numerous studies have examined the effect of PPARa activation
or deletion on hepatic gene regulation using transcriptomics. In
general, these studies indicate that unlike many other nuclear
receptors, PPARa governs the expression of a large set of genes,
many of which are involved in fatty acid metabolism [22–27].
However, there has been no systematic comparison of the whole
genome effects of PPARa activation in human versus mouse
hepatocytes [28]. Accordingly, in the present paper we systemat-
ically compared the effect of PPARa activation in primary mouse
and human hepatocytes using a whole genome transcriptomics
approach. A number of important general conclusions can be
drawn from our work. First, perhaps contrary to common
conception, our data support a major role for PPARa in human
liver, as evidenced by the large number of genes altered upon
PPARa activation in primary human hepatocytes. Second, even
though the human and mouse hepatocytes were not cultured under
identical conditions, we feel comfortable to conclude that PPARa
regulates a mostly divergent set of genes in mouse and human liver.
For example, we found that metabolism of xenobiotics is specifically
regulated by PPARa in human liver. Third, the role of PPARa as a
Figure 4. Heat map illustrating the species-specific regulation of two gene sets originating from Gene set enrichment analysis
(GSEA). (A) Glycolysis-gluconeogenesis as a mouse-specific upregulated gene set. (B) Xenobiotic metabolism as a human-specific upregulated gene
set. Genes are ranked based on the mean fold change (MFC). Expression levels in the DMSO-treated cells were set at 1.
doi:10.1371/journal.pone.0006796.g004
PPARa between Mouse and Human
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master regulator of hepatic lipid metabolism is well conserved
between mouse and human. However, within each lipid metabolic
pathway the specific genes under control of PPARa in mouse and
human differ to some extent.
In recent years, the role of PPARa in human liver has been
questioned based on RNase protection data showing 10-fold lower
levels of PPARa mRNA in human liver compared with mouse
liver [19]. Additionally, human hepatoma HepG2 cells were
shown to respond poorly to PPARa activation [21]. In contrast,
we show by quantitative realtime PCR that in liver tissue and
primary hepatocytes PPARa expression levels are similar between
mouse and human. It is inherently difficult to compare hepatic
PPARa expression between species as PPARa mRNA fluctuations
throughout the day [29], is increased by fasting [30], and is
reduced under conditions of inflammation [31]. Changes in
PPARa expression will likely influence the transcriptional response
to PPARa activation. Our comparative analysis of hepatic gene
regulation by human PPARa vs. mouse PPARa should thus be
considered an approximation. Despite the limitations, our analysis
represents a major advancement in our understanding of PPARa
function in human liver.
Consistent with a major role of PPARa in human hepatocytes,
the number of genes significantly regulated by Wy14643 was very
high and was similar to the number in mouse hepatocytes.
Although induction of gene expression by Wy14643 was generally
less robust in human hepatocytes, these cells likely lost some
sensitivity due to the extended time between isolation and
harvesting. We were able to exclude differences in cultured
medium as an explanation for the lower fold-inductions in human
hepatocytes (data not shown).
While the number of genes commonly regulated by PPARa in
mouse and human hepatocytes may seem relatively small, which
would suggest minor overlap in PPARa function between the two
species, the overlap is more impressive when studied at the level of
gene ontology. Many of the overlapping gene ontology classes
represent pathways of lipid metabolism. Supporting these data,
many of the 125 genes co-regulated by PPARa in mouse and
human are involved in various aspects of hepatic lipid handling,
including peroxisomal and mitochondrial fatty acid oxidation
(ACOX1, ECH1), ketogenesis (HMGCS2), fatty acid binding and
activation (FABP1, ACSL3), and fatty acid uptake (SLC27A2).
Our analysis demonstrates that in human liver, analogous to the
situation in mouse liver [26], PPARa serves as a global
transcriptional regulator of lipid metabolism.
In addition to numerous established PPARa target genes,
several genes were found to be co-regulated by Wy14643 in mouse
and human that have not yet been linked to PPARa, including the
liver specific transcription factor CREB3L3. CREB3L3 was
recently shown to be involved in the hepatic acute phase response,
suggesting that it may partially mediate the effects of PPARa on
acute phase response [32]. Other conserved novel putative targets
include MAP3K8, SGK2, and the transcription factor KLF10 and
KLF11. KLF10 and KLF11 encode three zinc-finger Kru¨ppel-like
transcription factors that binds GCrich/Sp1-like sequences and
influence cell proliferation [33].
The inability of PPARa agonists to induce peroxisome
proliferation in human is well acknowledged, although the precise
mechanism remains to be fully elucidated. Using humanized
PPARa mice, it has been shown that the human PPARa receptor
has the ability to induce peroxisome proliferation and peroxisomal
fatty acid oxidation in the context of a mouse liver [34,35].
However, in a previous study using HepG2 cells engineered to
express PPARa at levels similar to mouse liver, ACOX1 and other
peroxisomal genes were not induced by PPARa [36]. Similar
results were obtained in primary human hepatocytes treated with
fenofibrate [37]. In contrast, we find that a number of genes
involved in peroxisomal fatty acid oxidation, including the
prototypical PPARa targets ACOX1, ECH1, PEX11A, and
ACAA1, is commonly induced by PPARa in mouse and human.
Simultaneously, we find that induction by PPARa of numerous
other peroxisomal genes, including Ehhadh, Pxmp4, Acot4, and
Peci, is specific for mouse. Our data argue against a general
mechanism and suggest that any lack of conservation of PPARa-
dependent gene regulation between mouse and human must be
determined at the level of individual target genes.
Figure 5. Limited similarity in Wy14643-induced gene regula-
tion between mouse and human hepatocytes. Scatter plots
demonstrating similarities and differences in gene regulation by 6 h (A)
and 24 h (B) PPARa activation between human and mouse hepatocytes.
Graphs show fold-changes in gene expression after treatment with
Wy4643 in human hepatocytes (x-axis) and mouse hepatocytes (y-axis).
Selected genes that are upregulated specifically by Wy4643 in human
or mouse are indicated.
doi:10.1371/journal.pone.0006796.g005
PPARa between Mouse and Human
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Figure 6. Partial conservation of Wy14643-induced gene regulation between human and mouse hepatocytes. Heat map illustrating
the relative induction of the top 50 of upregulated genes in response to 6 h Wy14643 treatment in human hepatocytes. All genes were significantly
changed (P,0.05) and were ranked based on mean fold-change (MFC). Expression levels in the DMSO-treated cells were set at 1. Relative changes in
expression of the corresponding mouse orthologs in mouse hepatocytes are shown in parallel.
doi:10.1371/journal.pone.0006796.g006
PPARa between Mouse and Human
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Figure 7. Partial conservation of Wy14643-induced gene regulation between mouse and human hepatocytes. Heat map illustrating
the relative induction of the top 50 of upregulated genes in response to 6 h Wy14643 treatment in mouse hepatocytes. All genes were significantly
changed (P,0.05) and were ranked based on mean fold-change (MFC). Expression levels in the DMSO-treated cells were set at 1. Relative changes in
expression of the corresponding human orthologs in human hepatocytes are shown in parallel.
doi:10.1371/journal.pone.0006796.g007
PPARa between Mouse and Human
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Figure 8. PPARa serves as a global transcriptional regulator of lipid metabolism in mouse and human hepatocytes. Genes significantly
upregulated by Wy14643 and that function in lipid metabolism were classified into specific metabolic pathways. Separate pictures were created for
human hepatocytes (A) and mouse hepatocytes (B). Genes significantly upregulated by Wy14643 at both time points of 6 h and 24 h are shown in
bold. Genes significantly upregulated by Wy14643 in human and mouse hepatocytes are shown in red. Genes significantly upregulated by Wy14643
at one time point only are shown in normal font. Functional classification is based on a self-made functional annotation system of genes involved in
lipid metabolism.
doi:10.1371/journal.pone.0006796.g008
PPARa between Mouse and Human
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Previously, it was shown that APOA1, APOA2 and APOA5 are
upregulated by PPARa agonists, which was found to be specific for
humans [38–41]. While we confirm the human-specific upregula-
tion of APO2 and APOA5 by Wy14643, we could not confirm the
upregulation of APOA1 by Wy14643. Rather, we found a minor
but statistically significant decrease in APOA1 expression after 6 h
of Wy14643 treatment. The reason for this discrepancy is unclear
but may be related to the type of PPARa agonist used. Overall,
our data indicate that regulation of apolipoproteins A by PPARa is
specific for humans, which very likely accounts for the human
specific induction of plasma HDL levels by fibrates [42].
Several individual genes were identified that were also specifically
regulated by Wy14643 in human hepatocytes. This includes the
secreted mannose-binding lectin MBL2, which is an important
protein of the humoral innate immune system [43], and TSKU,
which encodes a secreted protein involved in development [44].
Regulation of CYP1A1 by PPARa in human hepatocytes has been
previously observed [45], and was shown here to be part of a more
comprehensive regulation of biotransformation enzymes by PPARa
that was specific for human hepatocytes. Importantly, while genes
belonging to the Cyp4a class are exclusively regulated by PPARa in
mouse, genes belonging to CYP classes 1–3 are specifically regulated
by PPARa in human, which confirms previous analyses [46,47].
A number of pathways was found to be specifically induced by
Wy14643 in mouse hepatocytes, including glycolysis/gluconeo-
genesis, pentose phosphate pathway, and glycerolipid metabolism,
as were several specific lipid metabolic pathways. A similar mouse-
specific response was observed at the level of individual genes.
Most notable examples were Fbp2 (fructose-1,6-bisphosphatase 2),
Lgals4 (lectin, galactoside-binding, soluble, 4), and several Acots
(Acyl-CoA thioesterases).
Studies in mice have yielded considerable evidence for a direct
role of PPARa in hepatic glucose metabolism. Importantly, fasted
PPARa -/- mice exhibit markedly reduced plasma glucose levels
[30]. Other studies have suggested a direct link between PPARa
and hepatic gluconeogenesis [48–50]. In contrast, human trials
generally do not support an effect of PPARa activation on plasma
glucose levels. Accordingly, it is tempting to relate these seemingly
discrepant results to the observed mouse-specific regulation of
glucose metabolic pathways.
In conclusion, PPARa activation has a major impact on gene
regulation in human liver cells. Importantly, the role of PPARa as
a master regulator of hepatic lipid metabolism is generally well
conserved between mouse and human. Overall, however, PPARa
regulates a mostly divergent set of genes in mouse and human
hepatocytes.
Materials and Methods
Materials
Wy14643 was obtained from ChemSyn Laboratories (Lenexa,
KS). Recombinant human insulin (Actrapid) was from Novo
Nordisk (Copenhagen, Denmark). SYBR Green was from
Eurogentec (Seraing, Belgium). Fetal calf serum, penicillin/
streptomycin/fungizone were from Lonza Bioscience (Verviers,
Belgium). Otherwise, chemicals were from Sigma (Zwijndrecht,
The Netherlands).
Human primary hepatocytes
Human hepatocytes and Hepatocyte Culture Medium Bulletkit
were purchased from Lonza Bioscience (Verviers, Belgium).
Primary hepatocytes were isolated from surgical liver biopsies
obtained from six individual donors who underwent surgery after
informed consent was obtained for surgery with subsequent use of
samples in experiments. Lonza utilizes the hospital’s Institutional
Review Board (IRB) to obtain approval before obtaining these
tissues. The characteristics of the donors are presented in Table 1.
Hepatocytes were isolated with two-step collagenase perfusion
method and the viability of the cells was over 80%.
Cells were plated on collagen-coated six-well plates and filled with
maintenance medium. Upon arrival of the cells, the medium was
discarded and was replaced by Hepatocyte Culture Medium
(HCM) with additives. The additives included Gentamicin
sulphate/Amphotercin-B, Bovine serum albumin (Fatty acid free),
Transferrin, Ascorbic acid, Insulin, Epidermal growth factor,
Hydrocortisone hemisuccinate. The next day, cells were incubated
in fresh medium in the presence or absence of Wy14643 (50 mM)
dissolved in DMSO for 6 and 24 hours, followed by RNA isolation.
Mouse primary hepatocytes
Mouse hepatocytes were isolated by two-step collagenase
perfusion as described previously [51] from 6 different strains of
mouse; NMRI, SV129, FVB, DBA, BALB/C and C57BL/6J.
The characteristics of the mice used are presented in Table 2.
Cells were plated on collagen-coated six-well plates. Viability was
determined by Trypan Blue exclusion, and was at least 75%.
Hepatocytes were suspended in William’s E medium (Lonza
Bioscience, Verviers, Belgium) supplemented with 10% (v/v) fetal
calf serum, 20 m-units/mL insulin, 10 nM dexamethasone, 100 U/
mL penicillin, 100 mg/mL of streptomycin, 0.25 mg/mL fungizone
and 50 mg/mL gentamycin. After four hours the medium was
discarded and replaced with fresh medium. The next day, cells were
incubated in fresh medium in the presence or absence of Wy14643
(10 mM) dissolved in DMSO for 6 and 24 hours, followed by RNA
isolation. Isolation of mouse primary hepatocytes was approved by
the animal ethics committee of Wageningen University. A 5-fold
lower concentration of Wy14643 was used in mouse primary
hepatocytes to take into account the higher affinity of Wy14643 for
mouse PPARa compared to human PPARa [52].
Table 1. Characteristics of the human liver donors.
Donors Age (years) Sex Pathology
Donor 1 63 Male Colo-rectal Metastasis
Donor 2 44 Male Metastasis
Donor 3 70 Female Hepatic metachrone lesion
Donor 4 54 Female Metastasis
Donor 5 73 Male Carcinome hepatocellular
Donor 6 73 Male Endocrine carcinoma
doi:10.1371/journal.pone.0006796.t001
Table 2. Characteristics of the mouse strains.
Mouse strain Age (months) Sex
NMRI 4 Male
BL/6 2 Male
Sv129 4 Male
FVB 5 Female
Balb/c 6 Male
DBA 3 Female
doi:10.1371/journal.pone.0006796.t002
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Affymetrix microarray
Total RNA was prepared from human and mouse primary
hepatocytes using TRIzol reagent (Invitrogen, Breda, The
Netherlands). RNA was used individually and further purified
using RNeasy micro columns (Qiagen, Venlo, the Netherlands).
RNA integrity was checked on an Agilent 2100 bioanalyzer
(Agilent Technologies, Amsterdam, the Netherlands) using 6000
Nano Chips according to the manufacturer’s instructions. RNA
was judged as suitable for array hybridization only if samples
exhibited intact bands corresponding to the 18S and 28S
ribosomal RNA subunits, and displayed no chromosomal peaks
or RNA degradation products (RNA Integrity Number.8.0). Five
hundred nanograms of RNA were used for one cycle cRNA
synthesis (Affymetrix, Santa Clara, CA). Hybridization, washing
and scanning of Affymetrix Gene chip mouse genome 430 2.0
arrays (mouse primary hepatocytes) and human genome U133 2.0
plus was according to standard Affymetrix protocols.
Scans of the Affymetrix arrays were processed using packages
from the Bioconductor project [53]. Expression levels of probe sets
were calculated using GCRMA, followed by identification of
differentially expressed probe sets using Limma. Comparison was
made between treated and untreated (control) human primary
hepatocyte, the same was compared for mouse primary hepato-
cyte. Probe sets that satisfied the criterion of Raw P,0.05 and a
mean fold-change.61.1 were considered to be significantly
regulated. These selection criteria were based on careful inspection
of the fold-changes in expression and their statistical significance of
some known PPARa target genes, including Acadvl, Fatp4, and
Acox1, which barely exceeded these thresholds. Functional
analysis of the array data was performed by a method based on
overrepresentation of Gene Ontology (GO) terms [54–56] and
Gene Set Enrichment analysis [57]. Orthologs were retrieved via
Homologene (NCBI). HomoloGene is a system for automated
detection of homologs among the annotated genes of several
completely sequenced eukaryotic genomes.
All Microarray data reported in the manuscript is described in
accordance with MIAME guidelines.
Q-PCR
1 mg of total RNA was reverse-transcribed with iScript (Bio-Rad,
Veenendaal, the Netherlands). cDNA was PCR-amplified with
Platinum Taq DNA polymerase (Invitrogen) on a Bio-Rad iCycler
or MyIQ PCR machine. Primers were designed to generate a PCR
amplification product of 100–200 bp and were taken from
Primerbank (http://pga.mgh.harvard.edu/primerbank). Specificity
of the amplification was verified by melt curve analysis and
evaluation of efficiency of PCR amplification. The sequence of
primers used are provided in Table S4. The mRNA expression of
genes reported was normalized to universal 18S gene expression. To
compare PPARa expression in mouse and human hepatocytes,
primers were used that yielded amplicons of equal length. A
standard curve was included to confirm amplification efficiency of
100%62 for PPARa and for the 18S control gene. PPARa
expression was calculated as 1/(2ˆ(CtPPARa a-Ct18S)), allowing for
direct comparison between the two species.
Human liver RNA was obtained via Ambion and represented a
mixture of RNA from 3 individuals without liver disease. Mouse
liver RNA was obtained from 5 male mice on mixed genetic
background (C57Bl/6-Sv129, fed state).
Supporting Information
Figure S1 Principal component analysis illustrating the major
sources of variation in our microarray dataset. In the first
dimension, data separate based on species. The second dimension
illustrates the effect of Wy14643 treatment.
Found at: doi:10.1371/journal.pone.0006796.s001 (9.28 MB TIF)
Figure S2 Heat map illustrating the relative induction of the top
50 of upregulated genes in response to 24 h Wy14643 treatment in
human hepatocytes. All genes were significantly changed (P,0.05)
and were ranked based on mean fold-change (MFC). Expression
levels in the DMSO-treated cells were set at 1. Relative changes in
expression of the corresponding mouse orthologs in mouse
hepatocytes are shown in parallel.
Found at: doi:10.1371/journal.pone.0006796.s002 (10.38 MB
TIF)
Figure S3 Species-specific induction of novel putative PPARa
genes by Wy14643. (A) Relative induction of Kruppel-like factor
10 (KLF10) by Wy14643 in human and mouse hepatocytes. (B)
Relative induction of Tukushin (TSKU) by Wy14643 in human
and mouse hepatocytes. (C) Relative induction of fructose
bisphosphatase 2 (Fbp2) by Wy14643 in mouse hepatocytes.
Inductions for 6 h (grey bars) and 24 h (black bars) Wy14643
treatments are shown. Expression of cells treated with DMSO was
set at 1 (white bars). Gene expression was determined by qPCR.
Error bars represent SD. *P,0.05 according to Student’s T-test.
Found at: doi:10.1371/journal.pone.0006796.s003 (4.08 MB TIF)
Figure S4 Heat map illustrating the relative induction of the top
50 of upregulated genes in response to 24 h Wy14643 treatment in
mouse hepatocytes. All genes were significantly changed (P,0.05)
and were ranked based on mean fold-change (MFC). Expression
levels in the DMSO-treated cells were set at 1. Relative changes in
expression of the corresponding human orthologs in human
hepatocytes are shown in parallel.
Found at: doi:10.1371/journal.pone.0006796.s004 (10.30 MB
TIF)
Table S1 Overlapping and species-specific list of significantly
upregulated (1_1) and downregulated (1_2) genes in mouse and
human primary hepatocytes after treatment with Wy14643 (6 h
and/or 24 h). Genes were designated as significantly changed if
satisfied the criteria of P,0.05 and mean fold change (MFC).61.1.
Found at: doi:10.1371/journal.pone.0006796.s005 (0.24 MB
XLS)
Table S2 Overlapping and species-specific list of Overrepre-
sented Gene Ontology Classes in mouse and human primary
hepatocytes after treatment with Wy14643 (6 h and/or 24 h),
based on a functional class score method, FDR,0.0001. GO
classes in bold font are species specifically overrepresented.
Found at: doi:10.1371/journal.pone.0006796.s006 (0.06 MB
XLS)
Table S3 Overlapping and species-specific list of induced gene
sets in mouse and human primary hepatocytes after treatment
with Wy14643 (6 h and/or 24 h), gene sets included between 15
and 250 genes and FDR,0.25.
Found at: doi:10.1371/journal.pone.0006796.s007 (0.02 MB
XLS)
Table S4 Sequences of primer pairs used.
Found at: doi:10.1371/journal.pone.0006796.s008 (0.03 MB
DOC)
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